Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT in San Francisco.
The presentation will be available via a live webcast on the company's investor website at www.beamtx.com and the webcast will be archived for 60 days after the presentation.
Details
News Market Reaction – BEAM
On Dec 19, the first trading day after this news, BEAM closed 1.53% above the previous close.
Data tracked by StockTitan Argus for the Dec 19 session.
Key Figures
- Conference date
- January 13, 2026
- Presentation at 44th Annual J.P. Morgan Healthcare Conference
- Presentation time
- 5:15 p.m. PT
- Scheduled time for J.P. Morgan Healthcare Conference presentation
- Webcast archive length
- 60 days
- Investor webcast available on company website after conference
- 52-week high
- $35.25
- Pre-news 52-week high for BEAM shares
- 52-week low
- $13.525
- Pre-news 52-week low for BEAM shares
- Market cap
- $2,715,469,501
- Pre-news market capitalization
Historical Context
-
Participation in Jefferies London Healthcare Conference with webcast access.
-
Updated BEACON Phase 1/2 BEAM-101 safety and efficacy data at ASH.
-
Planned participation in three major September 2025 investor conferences.
-
FDA RMAT designation for BEAM-101 in sickle cell disease with promising trial data.
-
Q2 2025 results and BEAM-302/BEAM-101 development updates with strong cash position.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
base editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San Francisco.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.